Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.